[A controlled clinical study of Pneumorel Retard tablets in the treatment of chronic bronchitis (author's transl)].
The authors studied the action of Pneumorel retard tablets in the treatment of chronic bronchitis, comparing 2 groups of 20 patients each, one group was prescribed 1 pneumorel retard tablet in the morning and evening and the other group was treated with a speciality associating proteolytic enzymes and balsamics; the 2 groups also received an antibiotic treatment. The duration of the treatments was 20 days, with controls at entry, 10 days and 20 days later. Pneumorel retard showed to be significantly more active on the criteria studied (cough, dyspnea, expectoration, signs of auscultation) and this more often than not from the 10th day of treatment. Clinical and biological tolerance was perfect concerning the hepatic sphere, gastrointestinal, renal or cardiovascular systems. The convenience of the use of Pneumorel retard is particularly indicated in the thorough long-term treatment of chronic bronchitis, in preventing episodes of over-infection, worsening the disease.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001453:Balsams / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000627:therapeutic use; D013141:Spiro Compounds / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D001453:Balsams; D013141:Spiro Compounds; D010447:Peptide Hydrolases
Etude clinique controlée du Pneumorel Retard comprimés dans la bronchite chronique.